Chronic Cholestatic Liver Injury Attributable to Vedolizumab

Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases res...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational hepatology 2016-09, Vol.4 (3), p.277-280
Main Authors: Stine, Jonathan G, Wang, Jennifer, Behm, Brian W
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.
ISSN:2225-0719
2310-8819
DOI:10.14218/JCTH.2016.00018